[HTML][HTML] Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
MK Kim, J Yee, YS Cho, HW Jang, JM Han, HS Gwak - BMC cancer, 2018 - Springer
Background Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC)
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
MK Kim, J Yee, YS Cho, HW Jang, JM Han, HS Gwak - BMC Cancer, 2018 - go.gale.com
Background Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC)
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
MK Kim, J Yee, YS Cho, HW Jang, JM Han… - BMC …, 2018 - search.ebscohost.com
Abstract < bold> Background: </bold> Erlotinib is a drug used for the treatment of
non-small cell lung cancer (NSCLC) and pancreatic cancer. Severe hepatotoxicity was …
non-small cell lung cancer (NSCLC) and pancreatic cancer. Severe hepatotoxicity was …
[PDF][PDF] Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
MK Kim, J Yee, YS Cho, HW Jang, JM Han, HS Gwak - 2018 - dspace.ewha.ac.kr
Background: Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC)
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
[HTML][HTML] Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
MK Kim, J Yee, YS Cho, HW Jang… - BMC …, 2018 - bmccancer.biomedcentral.com
Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC) and
pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients receiving …
pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients receiving …
Risk factors for erlotinib-induced hepatotoxicity: A retrospective follow-up study
MK Kim, J Yee, YS Cho, HW Jang, JM Han… - BMC Cancer, 2018 - pure.ewha.ac.kr
Background: Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC)
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
MK Kim, J Yee, YS Cho, HW Jang, JM Han… - BMC …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC)
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
MK Kim, J Yee, YS Cho, HW Jang, JM Han… - BMC Cancer, 2018 - europepmc.org
Background Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC)
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
MK Kim, J Yee, YS Cho, HW Jang, JM Han… - BMC …, 2018 - search.proquest.com
Background Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC)
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
[HTML][HTML] Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
MK Kim, J Yee, YS Cho, HW Jang, JM Han… - BMC Cancer, 2018 - ncbi.nlm.nih.gov
Background Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC)
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …